--- title: "Harrow: Strong Iheezo Demand and Confident 2026 Guidance Support Buy Rating Despite Near-Term Miss" type: "News" locale: "en" url: "https://longbridge.com/en/news/295460276.md" description: "William Blair analyst Lachlan Hanbury Brown maintained a Buy rating on Harrow (HROW), citing strong Iheezo demand and confident 2026 guidance despite a near-term earnings miss. He views the product traction and management's $350-$365 million revenue target as evidence of durable growth, justifying the bullish stance. B. Riley Securities also upheld a Buy rating with a $60 price target." datetime: "2026-08-10T22:45:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295460276.md) - [en](https://longbridge.com/en/news/295460276.md) - [zh-HK](https://longbridge.com/zh-HK/news/295460276.md) generator: "portal-rs" --- # Harrow: Strong Iheezo Demand and Confident 2026 Guidance Support Buy Rating Despite Near-Term Miss William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on HROW stock, giving a Buy rating today. ### Claim 55% Off TipRanks - Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions - Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Lachlan Hanbury Brown has given his Buy rating due to a combination of factors, including Harrow’s sustained demand for Iheezo and management’s reaffirmation of robust long‑term guidance despite a modest quarterly miss. He views the stronger‑than‑expected Iheezo uptake and the transition to new packaging as evidence of durable product traction that can drive meaningful revenue and margin expansion over time. He also highlights that management’s confidence in achieving 2026 revenue of $350 million to $365 million and adjusted EBITDA of $80 million to $100 million underscores a compelling growth trajectory relative to the current share price. While near‑term earnings were pressured by higher SG&A and second‑quarter revenue landed just below guidance, he believes these impacts are transitory and that the setup for a second‑half revenue inflection supports attractive upside, justifying a Buy recommendation. According to TipRanks, Hanbury Brown is an analyst with an average return of -0.3% and a 43.56% success rate. Hanbury Brown covers the Healthcare sector, focusing on stocks such as ARS Pharmaceuticals, Tarsus Pharmaceuticals, and LENZ Therapeutics. In another report released today, B. Riley Securities also maintained a Buy rating on the stock with a $60.00 price target. ### Related Stocks - [HROWL.US](https://longbridge.com/en/quote/HROWL.US.md) - [HROW.US](https://longbridge.com/en/quote/HROW.US.md) - [SPRY.US](https://longbridge.com/en/quote/SPRY.US.md) - [TARS.US](https://longbridge.com/en/quote/TARS.US.md) - [LENZ.US](https://longbridge.com/en/quote/LENZ.US.md) - [RILY.US](https://longbridge.com/en/quote/RILY.US.md) - [HROWM.US](https://longbridge.com/en/quote/HROWM.US.md) - [RILYL.US](https://longbridge.com/en/quote/RILYL.US.md) - [RILYG.US](https://longbridge.com/en/quote/RILYG.US.md) - [RILYN.US](https://longbridge.com/en/quote/RILYN.US.md) - [RILYK.US](https://longbridge.com/en/quote/RILYK.US.md) - [RILYP.US](https://longbridge.com/en/quote/RILYP.US.md) - [RILYZ.US](https://longbridge.com/en/quote/RILYZ.US.md) - [RILYT.US](https://longbridge.com/en/quote/RILYT.US.md) ## Related News & Research - [Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half](https://longbridge.com/en/news/296638124.md) - [Harrow Chief Scientific Officer Amir Shojaei disposes of 11,250 common shares worth $450,000](https://longbridge.com/en/news/296149417.md) - [Barclays Sticks to Its Buy Rating for Jack Henry & Associates (JKHY)](https://longbridge.com/en/news/296455498.md) - [Barclays Sticks to Its Buy Rating for ASR Nederland N.V (0RHS)](https://longbridge.com/en/news/296451125.md) - [Deutsche Bank Keeps Their Buy Rating on DocMorris (DOCM)](https://longbridge.com/en/news/296474032.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**